howev
preval
data
scarc
migrant
popul
studi
aim
evalu
preval
stercorali
hospit
level
migrant
popul
long
term
travel
attend
outpati
inpati
unit
part
systemat
screen
implement
spanish
hospit
crosssect
studi
conduct
systemat
screen
stercorali
infect
use
serolog
test
offer
elig
particip
overal
seropreval
stercorali
confid
interv
ci
seropreval
peopl
risk
infect
acquir
africa
latin
america
ci
respect
number
individu
come
asian
countri
significantli
smaller
overal
preval
countri
ci
one
case
individu
east
european
countri
seropreval
unit
attend
potenti
immunosuppress
patient
significantli
lower
compar
seropreval
unit
hospit
tropic
diseas
unit
p
conclus
report
hospitalbas
systemat
screen
strongyloidiasi
seropreval
almost
mobil
popul
come
endem
area
suggest
need
implement
strongyloidiasi
screen
hospit
patient
come
endem
area
particularli
risk
immunosuppress
strongyloidiasi
infect
caus
helminth
strongyloid
stercorali
ubiquit
tropic
subtrop
area
rest
countri
also
frequent
migrant
come
tropic
subtrop
area
diseas
sever
infect
subject
impair
immun
system
within
studi
evalu
preval
infect
peopl
attend
six
spanish
hospit
preval
around
higher
africa
latin
america
compar
region
addit
preval
patient
impair
immun
system
immunosuppress
lower
compar
peopl
non
suffer
immunosuppress
result
suggest
preval
strongyloidiasi
quit
high
among
migrant
live
spain
screen
programm
design
particularli
immunosuppress
patient
risk
suffer
sever
complic
infect
strongyloidiasi
prevail
helminth
infect
ubiquit
tropic
subtrop
area
howev
preval
data
scarc
migrant
popul
studi
aim
evalu
preval
stercorali
hospit
level
migrant
popul
long
term
travel
attend
outpati
inpati
unit
part
systemat
screen
implement
spanish
hospit
crosssect
studi
conduct
systemat
screen
stercorali
infect
use
serolog
test
offer
elig
particip
overal
seropreval
stercorali
confid
interv
strongyloidiasi
infect
caus
helminth
strongyloid
stercorali
ubiquit
tropic
subtrop
area
rest
countri
also
frequent
migrant
come
tropic
subtrop
area
diseas
sever
infect
subject
impair
immun
system
within
studi
evalu
preval
infect
peopl
attend
six
spanish
hospit
preval
around
higher
africa
latin
america
compar
region
addit
preval
patient
impair
immun
system
immunosuppress
lower
compar
peopl
non
suffer
immunosuppress
result
suggest
preval
strongyloidiasi
quit
high
among
migrant
live
spain
screen
programm
design
particularli
immunosuppress
patient
risk
suffer
sever
complic
infect
public
health
impact
nonendem
countri
host
popul
infect
ubiquit
tropic
subtrop
area
although
may
also
occur
temper
countri
appropri
condit
certain
area
spain
itali
worldwid
estim
base
standard
faecal
techniqu
suggest
million
peopl
worldwid
infect
figur
may
underestim
due
low
sensit
tradit
diagnost
method
unlik
parasit
infect
helminth
characterist
particular
import
migrant
popul
first
place
infect
persist
whole
lifetim
due
abil
replic
human
host
therefor
peopl
come
endem
area
may
risk
whole
life
irrespect
moment
arriv
nonendem
area
long
treat
second
strongyloid
stercorali
infect
gener
asymptomat
caus
unspecif
symptom
unnot
health
profession
look
third
although
infect
rare
transmit
person
person
transmit
organ
transplant
autochthon
case
report
nonendem
area
thu
screen
consid
potenti
donor
risk
infect
final
case
immunosuppress
particularli
describ
concomit
use
steroid
transplant
recipi
patient
malign
human
tcell
lymphotrop
coinfect
parasit
may
enter
high
replic
cycl
call
hyperinfect
dissemin
vital
organ
dissemin
strongyloidiasi
caus
sever
diseas
high
mortal
regard
immunosuppress
permit
larval
prolifer
hyperinfect
diseas
also
dissemin
organ
dissemin
strongyloid
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
diagnosi
strongyloidiasi
nonendem
area
reinfect
unlik
current
base
serolog
test
consider
higher
sensit
compar
standard
faecal
techniqu
despit
crossreact
helminth
infect
fact
less
like
occur
migrant
popul
sinc
possibl
coinfect
lower
therefor
nowaday
current
recommend
screen
techniqu
popul
sensit
serolog
test
immunosuppress
individu
seem
lower
limit
data
prospect
studi
better
evalu
accuraci
serolog
test
immunosuppress
patient
even
limit
current
diagnost
method
screen
highrisk
group
treatment
infect
individu
key
import
regard
screen
strongyloidiasi
newli
arriv
migrant
recommend
european
centr
diseas
prevent
control
particularli
immunosuppress
individu
given
potenti
individu
morbid
mortal
evid
preval
strongyloidiasi
migrant
popul
scarc
although
known
vari
substanti
depend
countri
origin
particularli
high
countri
cambodia
latin
american
countri
hospitalbas
preval
studi
conduct
special
unit
suggest
preval
stercorali
migrant
popul
avail
data
suggest
higher
preval
infect
immunosuppress
individu
risk
studi
aim
evalu
preval
stercorali
hospit
level
migrant
popul
long
term
travel
attend
outpati
inpati
unit
part
systemat
screen
implement
spanish
hospit
crosssect
studi
carri
part
hospitalbas
prospect
cohort
studi
conduct
refer
hospit
spain
hospit
clinic
hospit
del
mar
hospit
universitari
bellvitg
hospit
sant
pau
hospit
vall
dhebron
locat
barcelona
hospit
de
ponient
almeria
provinc
aim
evalu
preval
risk
factor
associ
strongyloid
stercorali
infect
particularli
relat
immunosuppress
patient
although
systemat
screen
wide
implement
nation
level
establish
individu
either
hospit
attend
special
outpati
inpati
unit
hospit
screen
strongyloidiasi
hospit
unit
depart
particip
studi
particular
infecti
diseas
tropic
unit
unit
attend
sever
immunosuppress
patient
will
particip
implement
systemat
screen
migrant
adult
individu
adult
longterm
travel
defin
stay
one
year
endem
countri
systemat
offer
screen
strongyloid
stercorali
base
serolog
test
endem
countri
consid
countri
asia
oceania
africa
east
european
countri
latin
american
countri
therefor
inclus
criteria
resid
endem
countri
one
year
attend
hospit
reason
irrespect
level
immunosuppress
part
programm
individu
met
inclus
criteria
screen
offer
test
stercorali
infect
serolog
blood
test
posit
patient
invit
particip
sign
consent
form
provid
treatment
ivermectin
mcgkg
consecut
day
particip
clinic
microbiolog
follow
six
month
therapi
part
routin
clinic
practic
ccbi
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
serum
sampl
test
specif
antibodi
use
commerci
enzym
link
immunosorb
assay
elisa
assay
accord
manufactur
instruct
singl
elisa
test
use
strongyloidiasi
elisa
kit
base
ivd
strongyloid
stercorali
crude
antigen
reduc
interlaboratori
variabl
intern
workshop
carri
start
studi
standard
serolog
techniqu
also
interpret
result
posit
sampl
defin
absorb
greater
od
unit
absorb
studi
calcul
valu
use
cutoff
base
seropreval
studi
conduct
nonendem
area
estim
preval
stercorali
cohort
base
data
estim
screen
individu
month
recruit
case
strongyloidiasi
consid
alfa
error
lost
followup
categor
variabl
describ
use
frequenc
distribut
median
interquartil
rang
use
describ
age
countri
origin
subsequ
group
differ
geograph
area
accord
criteria
could
precis
identifi
migrat
pattern
geosentinel
geograph
area
distribut
select
preval
point
estim
confid
interv
ci
obtain
use
fisher
exact
test
compar
percentag
data
manag
analys
use
stata
built
world
map
countri
acquisit
preval
use
free
softwar
qgi
version
studi
report
follow
strobe
statement
strengthen
report
observ
studi
epidemiolog
report
observ
studi
annex
women
higher
seropreval
compar
men
pvalu
found
associ
age
group
preval
p
seropreval
peopl
risk
infect
acquir
africa
ci
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
number
individu
screen
come
asian
countri
significantli
smaller
overal
preval
countri
ci
case
observ
peopl
come
southeast
asia
ci
origin
philippin
seropreval
one
case
individu
east
european
countri
patient
montenegro
travel
outsid
europ
individu
origin
west
europ
also
screen
sstercorali
long
term
travel
endem
countri
individu
posit
result
countri
acquisit
could
identifi
sinc
undertaken
trip
sever
endem
area
past
latin
america
south
east
asia
countri
seropreval
unit
attend
immunosuppress
potenti
immunosuppress
unit
rate
individu
la
origin
respect
significantli
lower
compar
unit
studi
show
overal
preval
almost
consist
studi
conduct
migrant
popul
live
nonendem
area
one
first
studi
evalu
result
systemat
screen
potenti
immunosuppress
patient
diseas
may
sever
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
high
preval
found
studi
support
need
screen
strategi
patient
potenti
immunosuppress
particularli
subsaharan
african
latin
american
migrant
potenti
immunosuppress
peopl
higher
risk
develop
sever
complic
diseas
extens
report
elsewher
howev
probabl
develop
hyperinfect
dissemin
infect
highrisk
immunosuppress
popul
unclear
systemat
screen
recent
recommend
highrisk
popul
come
endem
area
howev
programm
report
result
far
regard
refer
centr
austria
initi
screen
sstercorali
transplant
recipi
show
preval
even
though
small
percentag
migrant
east
european
countri
interestingli
seropreval
ecuador
also
bolivia
much
higher
compar
la
countri
similar
compar
studi
conduct
migrant
countri
may
partial
explain
due
profil
migrant
come
rural
area
countri
addit
sampl
countri
may
also
overrepres
compar
la
countri
therefor
preval
la
may
overestim
geograph
area
southeast
asia
north
africa
data
show
neglig
rate
seropreval
higher
countri
morocco
philippin
found
publish
seropreval
data
countri
although
limit
sampl
may
prevent
extract
conclus
real
preval
countri
data
refut
need
consid
pool
countri
screen
recommend
data
asian
countri
still
scarc
limit
sampl
may
prevent
extract
proper
conclus
regard
preval
geograph
area
although
found
studi
provid
specif
preval
estim
asian
migrant
surveil
data
ccbi
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
health
condit
migrant
report
strongyloidiasi
among
diagnosi
peopl
come
southeast
asia
south
asian
countri
studi
nonendem
area
better
evalu
stercorali
preval
peopl
come
asian
countri
seropreval
women
found
significantli
higher
compar
men
differ
studi
preval
frequent
male
popul
databas
countri
like
bolivia
high
seropreval
larger
proport
women
fact
may
partial
explain
differ
studi
preval
hivinfect
individu
transplant
unit
much
lower
compar
gener
outinpati
unit
servic
hospit
one
possibl
explan
could
contribut
lower
preval
found
potenti
immunosuppress
patient
serolog
lower
sensit
immunosuppress
patient
report
studi
sensit
serolog
immunosuppress
patient
deserv
evalu
accuraci
sinc
studi
evalu
show
lower
sensit
compar
parasitolog
techniqu
hospitalbas
studi
result
interpret
context
hospitalbas
popul
gener
preval
result
gener
wider
popul
done
caution
sinc
posit
select
bia
taken
account
addit
anoth
limit
differ
preval
hospit
particip
studi
could
partial
explain
differ
migrant
profil
howev
lack
systemat
screen
could
overestim
preval
case
report
hospitalbas
systemat
screen
strongyloid
seropreval
almost
migrant
popul
endem
area
put
evid
need
implement
strongyloidiasi
screen
strategi
hospit
patient
particularli
risk
immunosuppress
work
fund
spanish
societi
tropic
medicin
intern
health
isglob
partial
support
ricet
ricet
within
spanish
nation
plan
r
cofund
isciii
feder
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
